Premium
Neutrophilic superoxide production can assess pharmacological and pharmacogenetic β‐adrenoreceptor effects
Author(s) -
Reinartz M. T.,
Wetzke M.,
Happle C.,
Kälble S.,
Scherer R.,
Kabesch M.,
Seifert R.
Publication year - 2016
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.12918
Subject(s) - pharmacogenetics , ex vivo , asthma , medicine , atopy , superoxide , in vivo , immunology , pharmacology , genotype , population , agonist , context (archaeology) , bronchodilator , biology , receptor , gene , genetics , biochemistry , environmental health , enzyme , paleontology
Asthma can be controlled well in most patients by inhaled β‐adrenoreceptor (β 2 AR ) agonists and steroids. Poor response to β 2 AR agonists is difficult to predict, especially in young children and by lung function testing, which may be affected by multiple influences. As an alternative approach, we analyzed ex vivo neutrophilic superoxide inhibition in response to β 2 AR stimulation. In 60 healthy volunteers, this assay was unaffected by sex, age, smoking, atopy or asthma status. Furthermore, we assessed effects of genetic variants in β 2 AR by sequencing the ADRB 2 gene in our cohort and relating genotypes to β 2 AR ‐mediated neutrophilic superoxide inhibition. Gly16Arg genotypes correlated with minor decrease in overall adrenoresponse in this small study population. Taken together, ex vivo testing of the β 2 AR response in human neutrophils represents a robust tool with good signal‐to‐noise ratio at physiological β 2 AR agonist concentrations, and this assay may be useful to complement future pharmacogenetic studies in asthma.